Pharma Update
Costs
R&D spend per NME launch
Roche spend is above industry average
R&D spend per NME launch², bn USD, 2018-20221
6.2
6.1
5.8
5.7
5.1
5.1
4.4
4.3
4.2
3.9
3.3
2.8
Peer 1
Peer 2
Peer 3
Roche
Peer 4
Peer 5
Peer 6
Peer 7
Peer 8
Peer 9
Peer 10
Peer 11
1. Average annual pharmaceutical R&D Spend from 2018-2022 (device and generics R&D spend excluded whenever reported separately). Pre-acquisition R&D spend for mega-merged entities (M&A >$10Bn) is included to
account for NME pipeline continuity; Only asset products sales included; 2. Restricted to NMEs launched 2018-23 with visible revenues for that company (any year in visible forecast data). NME = New Molecular Entity
(including novel biologics). Partnered launches can be assigned to multiple companies if there are revenues associated with several players; Source: Evaluate Pharma March 2023
04.7
Roche
26View entire presentation